SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced the appointment ofThomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D. to itsScientific Advisory Board(SAB).The SAB comprises experts across oncology, immunology, cell therapy, and drug discovery and development.

We areprivileged to welcome Drs. Gajewski and Grupp to our Scientific Advisory Board, saidRafael Amado, M.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene. The additions of Dr. Gajewski and Dr. Grupp further enhance what has become one of the most distinguished cell therapy SABs in the industry and is an important component of our strategy to lead the development of allogeneic cell therapies today and tomorrow.

New Allogene SAB members:

The new advisors join existing SAB members, Chairman Ton Schumacher, Ph.D.,Donald B. Kohn, M.D., Malcolm K. Brenner, M.D., Ph.D.,Matthew Porteus, M.D., Ph.D., Owen Witte, M.D., Stephen J. Forman, M.D., and Wendell Lim, Ph.D.

About Allogene TherapeuticsAllogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stagebiotechnology company pioneering the development of allogeneic chimeric antigen receptor Tcell (AlloCAR T) therapies for cancer. Led by a management team with significantexperience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell therapycandidates with the goal of delivering readily available cell therapy on-demand, more reliably, and atgreater scale to more patients. For more information, please visitwww.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogenes expectations and actual results as discussed in greater detail in Allogenes filings with the SEC, including without limitation in its Form 10-Q for the quarter ended March 31, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Kymriah is a registered trademark of Novartis Pharmaceuticals Corporation.AlloCAR T is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:Christine CassianoChief Communications Officer(714) 552-0326Christine.Cassiano@allogene.com

Read more here:
Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, MD, Ph.D., and Stephan Grupp, MD, Ph.D., to its Scientific Advisory Board -...